Jul 29, 2026

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)
• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
• Risk Assessment for Patients with HR-Positive,...

Jul 25, 2026

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

• Introduction (0:00)
• Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor...

Jul 18, 2026

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

• Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
• Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or...

Jul 17, 2026

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics:

·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00)

·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of...

Jul 13, 2026

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction: ODAC — April 30, 2026 (00:00)
• Adjuvant CDK4/6 Inhibitors (13:03)
• Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
• Premenopausal Patients (30:52)
• Duration of Adjuvant Endocrine...